Skip to content

The GBA Multimodal Study in Parkinson's Disease

Parkinson Disease | GBA Gene Mutation | Gaucher Disease

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:

* heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
* age 18 to 80 years.

Exclusion Criteria:

* co-occurrence of other neurological disorders;
* implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
* severe claustrophobia;
* intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
* ongoing treatment with cholinergic drugs

Study Location

Pacific Parkinson's Research Centre | University of British Columbia
Pacific Parkinson's Research Centre | University of British Columbia
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Jess McKenzie

[email protected]
(604) 822-7764
Study Sponsored By
Pacific Parkinson's Research Centre
Participants Required
More Information
Study ID: NCT04101968